Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0Y3JI
|
|||
| Former ID |
DIB003176
|
|||
| Drug Name |
DG-17
|
|||
| Synonyms |
DG-35; Nar DG-35 Prodrug; DG-35-VIII
Click to Show/Hide
|
|||
| Indication | Human immunodeficiency virus infection [ICD-11: 1C62; ICD-9: 279.3] | Phase 2 | [1] | |
| Company |
Narhex Life Sciences Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Human immunodeficiency virus Protease (HIV PR) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Narhex Life Sciences Limited announced a successful capital raising via a combined Rights Issue and Placement offering. 21 May 2007. | |||
| REF 2 | Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999 April 16; 13(6): 661-667. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.